Arch Therapeutics, Inc. Breaking 52 Week High

Arch Therapeutics, Inc. Breaking 52 Week High

Arch Therapeutics, Inc. (OTCQB: ARTH), developer of the AC5 Surgical Hemostatic Device, has garnered some interest by retail investors as the stock broke through its 52 week high of $0.45 with above average volume. Arch announced last month they obtained favorable results from a broad panel of preclinical biocompatibility tests that were performed on AC5, which is required prior to the planned filing of a CE Mark application and commercialization of AC5 in Europe.

Related posts

Leave a Comment

* Copy This Password *

* Type Or Paste Password Here *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>